Going Once, Going Twice, Sold! Cinven and Bain Capital to Acquire STADA for €5.3bn after Intense Bidding War

Stada Arzneimittel AG (FWB: SAZ) – market cap as of 21/04/2017: €4.02bn Intel Cinven Partners LLP – private company – AUM as of FY 2015: €10.60bn Bain Capital Private Equity, LP – private company – AUM as of 04/04/2017: $32.40bn Introduction On April 10, 2017, Bain Capital Private Equity, LP Read more…

Times are Smoking Hot! – BAT to Acquire the Remaining Stake in Reynolds for $47bn

British American Tobacco Plc. (BATS)—market cap as of 28/10/16: £87.26bn Reynolds American, Inc. (RAI)—market cap as of 28/10/16: $78.16bn Introduction On October 21, 2016, British American Tobacco (“BAT”) delivered a non-binding merger proposal to Reynolds American Inc. (“Reynolds”). Through this $47bn deal, BAT will acquire the remaining 57.8% of Reynolds’ Read more…

Telecom industry “calls” for consolidation: threats and opportunities in the Italian market

We all know the strong changes that Internet has brought to our everyday lives; the way people are connected and communicate has changed dramatically over the past years. Phone calls and standard text messages are becoming less and less popular, as alternative communication services and apps like WhatsApp or Messenger Read more…

Starwood – Marriott: Star Marriage or a Walkaway?

Starwood Hotels & Resorts Worldwide Inc.; Market Cap: $12.18bn (as of 19/11/2015) Marriott International Inc.; Market Cap: $ 18.64bn (as of 19/11/2015)   Introduction On November 16, Marriott International, Inc. (NASDAQ:MAR) and Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT) announced that the boards of directors of both companies unanimously Read more…

Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal

Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn   Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…